SIGA Technologies appoints Phil Gomez as CEO
Dr. Gomez brings decades of experience in drug development as well as deep management and business expertise. Most recently, he served as a Principal at PricewaterhouseCoopers LLP in the Pharma & Life Sciences Management Consulting practice.
At PwC, and at PRTM prior its acquisition by PwC, Dr. Gomez led the development and execution of business strategies for leading pharmaceutical companies.
In addition, he has advised companies, governments, academic medical centers, and foundations in the fields of Biodefense and Global Public Health.
Prior to joining PwC and PRTM, Dr. Gomez worked at the National Institutes of Health in Bethesda, MD, where he established the Vaccine Production Program at the Vaccine Research Center in 2001.
During his six-year tenure, his group manufactured more than 40 bulk pharmaceutical compounds and more than 15 candidate vaccines to advance the development of vaccines against HIV, Ebola, West Nile Virus, Marburg, Severe Acute Respiratory System (SARS), and Influenza.
In 2007 Dr. Gomez earned the NIH Director's Award for the establishment of the vaccine pilot plant and for the rapid production of a candidate pandemic influenza vaccine.
He spent nearly a decade in the pharmaceutical industry at Abbott Laboratories, Sanofi Pasteur, and Baxter Healthcare leading process/product development organizations as well as project teams for product development.
Current CEO Dr. Eric Rose will become Executive Chairman of the Board of Directors.
Dr. Rose has been Chairman of the Board since 2007. Dr. Rose was elected Chairman of the Board of Directors on January 25, 2007, and, on March 1, 2007, became the company’s CEO.
He has served as a director of SIGA since April 19, 2001 and served as Interim Chief Executive Officer of SIGA during April-June 2001.
Dr. Rose chaired the Department of Health Evidence & Policy at the Mount Sinai School of Medicine from 2008 to 2012, which he now serves as co-chair and professor.
From 1994 through 2007, he served as Chairman of the Department of Surgery and Surgeon-in-Chief of the Columbia Presbyterian Center of New York Presbyterian Hospital.
In addition to his roles at SIGA, Dr. Rose holds a position of Executive Vice President – Life Sciences at MacAndrews & Forbes Incorporated, a SIGA shareholder. ■
LATEST MOVES FROM New York
- Verizon Communications appoints Rima Qureshi as EVP
- Bristol-Myers Squibb appoints Karen Vousden to board
- Tonix Pharmaceuticals appoints Margaret Smith Bell to board
- 21st Century Fox promotes Peter Rice to president
- Iconix Brand Group hires June K. DeFabio as EVP
More inside POST
Freddie Mac Q2 net loss $322 million Earnings